Effects of Resveratrol Supplementation on Oocyte Quality

Launched by CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA, E.P.E. · Jan 30, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at whether taking a supplement called resveratrol can improve the quality of eggs in women aged 35 to 40 who are experiencing infertility and are planning to undergo in vitro fertilization (IVF). Over a period of three months, participants will take either a daily capsule of resveratrol or a placebo (a non-active pill that looks the same) before starting their IVF treatment. The goal is to see if resveratrol can help make the eggs healthier, which could lead to better outcomes for women trying to conceive.

To be eligible for this trial, women must be aged 35 to 40 and undergoing IVF. However, certain conditions would exclude them from participating, such as having severe male fertility issues, low ovarian reserve, or specific health conditions like diabetes. It's important to note that this trial is not currently recruiting participants, but it aims to help women in this age group who are struggling with infertility by testing a potential new way to enhance egg quality.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women with infertility undergoing IVF/ICSI
• • Ovarian stimulation with GnRH-antagonist protocol
• • Age 35-40 years old
• Exclusion Criteria:
• • Severe male factor (oligospermia or azoospermia)
• • Low ovarian reserve (AMH \< 1.1. ng/mL)
• • Poor response to ovarian stimulation (\< 3 oocytes)
• • Polycystic ovarian syndrome (Rotterdam criteria)
• • Ovarian endometriosis (endometrioma \> 30 mm)
• • Uterine anomalies (congenital or acquired)
• • Diabetes Mellitus
• • Concurrent use of any vitamin (except folic acid)